The Risk of Major Bleeding With Novel Anti-platelets: A Comparison of Ticagrelor With Clopidogrel in a Real World Population of 5000 Patients Treated for Acute Coronary Syndrome

• Status: Completed
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: All

Summary

A retrospective real world analysis of bleeding events with ticagrelor compared to clopidogrel in ACS patients.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aintree University Hospitals NHS Foundation Trust; Liverpool University Hospitals NHS Foundation Trust
• Collaborators: Countess of Chester NHS Foundation Trust; Liverpool Heart and Chest Hospital NHS Foundation Trust; Royal Liverpool and Broadgreen University Hospitals NHS Trust; St Helens & Knowsley Teaching Hospitals NHS Trust
• Treatments: Clopidogrel; Ticagrelor; Ticlopidine

Criteria

Inclusion Criteria:

1. Patient commenced on clopidogrel for ACS prior to change of ACS guidelines, or tiacgrelor for same indication afterwards.

Exclusion Criteria:

1. Patient already taking the drug in question (clopidogrel or ticagrelor) prior to the ACS event

2. Patients under 18 years of age

3. Patients in whom the drug is stopped during the same hospital admission due to clinical judgement dictating that it is no longer indicated (this does not apply to patients in whom a bleeding event is the precipitant for stopping the drug)